TAK-573 + pomalidomide + dexamethasone

TAK-573 + pomalidomide + dexamethasone is a combination regimen under investigation primarily for the treatment of **relapsed or refractory multiple myeloma**. TAK-573, also known as modakafusp alfa, is a novel **engineered fusion protein** that targets the **CD38 antigen** on plasma cells, linking an anti-CD38 monoclonal antibody to two interferon-alpha2b molecules, delivering targeted immune modulation and direct cytotoxicity. **Pomalidomide** is an **immunomodulatory drug** (IMiD) that works by degrading the transcription factors Ikaros and Aiolos (IKZF1/3), leading to antiproliferative and proapoptotic activity in malignant plasma cells. **Dexamethasone** is a synthetic corticosteroid, used for its anti-inflammatory and lympholytic (lymphocyte-reducing) effects. This combination aims to exploit direct tumoricidal activity, immune activation, and anti-inflammatory mechanisms to overcome resistance in multiple myeloma, particularly in patients previously treated with other modalities. The combination is currently being evaluated in **early-phase clinical trials** for safety, clinical efficacy, and optimal dosing in multiple myeloma[3][4].

Other names

modakafusp alfa + pomalidomide + dexamethasone